 Stephen Dreskin
Concepts (476)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peanut Hypersensitivity | 27 | 2025 | 143 | 6.990 |
Why?
| | Immunoglobulin E | 42 | 2025 | 315 | 6.220 |
Why?
| | Antigens, Plant | 23 | 2025 | 55 | 5.650 |
Why?
| | 2S Albumins, Plant | 20 | 2025 | 31 | 5.510 |
Why?
| | Allergens | 23 | 2023 | 386 | 4.880 |
Why?
| | Arachis | 19 | 2023 | 108 | 4.080 |
Why?
| | Glycoproteins | 12 | 2016 | 354 | 2.610 |
Why?
| | Epitopes | 9 | 2025 | 473 | 2.420 |
Why?
| | Urticaria | 11 | 2018 | 38 | 2.390 |
Why?
| | Omalizumab | 3 | 2024 | 43 | 1.440 |
Why?
| | Mast Cells | 13 | 2021 | 148 | 1.420 |
Why?
| | Basophils | 14 | 2018 | 52 | 1.390 |
Why?
| | Desensitization, Immunologic | 3 | 2019 | 89 | 1.010 |
Why?
| | Food Hypersensitivity | 3 | 2020 | 164 | 0.850 |
Why?
| | Benzoquinones | 4 | 2007 | 46 | 0.760 |
Why?
| | Nuts | 2 | 2023 | 13 | 0.700 |
Why?
| | Anaphylaxis | 3 | 2018 | 102 | 0.650 |
Why?
| | Anti-Allergic Agents | 3 | 2018 | 40 | 0.650 |
Why?
| | Receptors, IgE | 11 | 2003 | 43 | 0.640 |
Why?
| | Seeds | 1 | 2020 | 69 | 0.620 |
Why?
| | Amino Acid Sequence | 8 | 2025 | 2131 | 0.620 |
Why?
| | Plant Proteins | 6 | 2023 | 111 | 0.610 |
Why?
| | Peptide Library | 2 | 2017 | 91 | 0.610 |
Why?
| | Peptide Mapping | 1 | 2019 | 62 | 0.600 |
Why?
| | Amino Acids | 1 | 2023 | 519 | 0.590 |
Why?
| | Allergists | 1 | 2018 | 13 | 0.560 |
Why?
| | Protein Conformation | 5 | 2022 | 938 | 0.550 |
Why?
| | Allergy and Immunology | 1 | 2018 | 43 | 0.540 |
Why?
| | Peptides | 7 | 2025 | 999 | 0.540 |
Why?
| | Immunoglobulin G | 7 | 2022 | 892 | 0.520 |
Why?
| | Rhinitis, Allergic, Seasonal | 3 | 2008 | 25 | 0.510 |
Why?
| | Plant Extracts | 3 | 2018 | 188 | 0.510 |
Why?
| | Bortezomib | 1 | 2016 | 54 | 0.490 |
Why?
| | Anti-Inflammatory Agents | 4 | 2008 | 478 | 0.470 |
Why?
| | Protein Binding | 6 | 2025 | 2240 | 0.460 |
Why?
| | Drug Hypersensitivity | 2 | 2013 | 90 | 0.460 |
Why?
| | Antibodies, Anti-Idiotypic | 2 | 2014 | 50 | 0.460 |
Why?
| | Interleukin-5 | 2 | 2008 | 39 | 0.450 |
Why?
| | Epitope Mapping | 3 | 2025 | 61 | 0.450 |
Why?
| | Hypersensitivity, Immediate | 4 | 2013 | 41 | 0.440 |
Why?
| | Humans | 74 | 2025 | 145783 | 0.440 |
Why?
| | Models, Molecular | 2 | 2016 | 1599 | 0.410 |
Why?
| | Proteome | 1 | 2018 | 513 | 0.390 |
Why?
| | Cell Degranulation | 3 | 2014 | 40 | 0.390 |
Why?
| | Animals | 33 | 2022 | 38101 | 0.380 |
Why?
| | Cross Reactions | 4 | 2023 | 130 | 0.370 |
Why?
| | Pharmacy Service, Hospital | 1 | 2013 | 89 | 0.350 |
Why?
| | Autoimmunity | 3 | 2013 | 933 | 0.340 |
Why?
| | Clinical Protocols | 1 | 2013 | 280 | 0.340 |
Why?
| | Compensation and Redress | 1 | 2011 | 8 | 0.330 |
Why?
| | National Health Programs | 1 | 2011 | 23 | 0.330 |
Why?
| | Autoimmune Diseases | 2 | 2013 | 469 | 0.320 |
Why?
| | Influenza Vaccines | 3 | 2013 | 534 | 0.320 |
Why?
| | Phosphatidylinositols | 6 | 1995 | 58 | 0.320 |
Why?
| | B-Lymphocytes | 1 | 2016 | 872 | 0.320 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2010 | 88 | 0.310 |
Why?
| | Leukemia, Basophilic, Acute | 5 | 1995 | 5 | 0.310 |
Why?
| | Rats | 16 | 2015 | 5585 | 0.310 |
Why?
| | Hydroxyproline | 2 | 2023 | 18 | 0.310 |
Why?
| | HLA-DR Antigens | 1 | 2010 | 220 | 0.300 |
Why?
| | Antibodies | 1 | 2011 | 397 | 0.290 |
Why?
| | Chronic Disease | 8 | 2018 | 1812 | 0.290 |
Why?
| | Thyroid Gland | 2 | 2009 | 91 | 0.290 |
Why?
| | Immune Tolerance | 1 | 2011 | 385 | 0.280 |
Why?
| | Type C Phospholipases | 5 | 1995 | 69 | 0.280 |
Why?
| | Eosinophils | 2 | 2021 | 316 | 0.270 |
Why?
| | Thimerosal | 1 | 2007 | 6 | 0.270 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2014 | 992 | 0.260 |
Why?
| | Phagocyte Bactericidal Dysfunction | 4 | 1987 | 11 | 0.250 |
Why?
| | Job Syndrome | 4 | 1987 | 6 | 0.250 |
Why?
| | Bone Marrow Cells | 2 | 2016 | 322 | 0.240 |
Why?
| | HLA-D Antigens | 1 | 2006 | 30 | 0.240 |
Why?
| | Receptors, Fc | 4 | 1991 | 54 | 0.240 |
Why?
| | Leukotrienes | 1 | 2006 | 28 | 0.240 |
Why?
| | Disease Models, Animal | 7 | 2018 | 4568 | 0.230 |
Why?
| | Respiratory Hypersensitivity | 1 | 2006 | 65 | 0.230 |
Why?
| | Hypersensitivity | 3 | 2008 | 254 | 0.230 |
Why?
| | Angioedema | 2 | 2010 | 16 | 0.220 |
Why?
| | Cell Line | 8 | 2019 | 2823 | 0.220 |
Why?
| | Isoenzymes | 2 | 2003 | 295 | 0.220 |
Why?
| | RNA, Messenger | 4 | 2007 | 2805 | 0.220 |
Why?
| | Vaccination | 2 | 2011 | 1428 | 0.220 |
Why?
| | Molecular Sequence Data | 6 | 2015 | 2883 | 0.220 |
Why?
| | Transcriptional Activation | 1 | 2007 | 372 | 0.210 |
Why?
| | Tumor Cells, Cultured | 8 | 2003 | 887 | 0.210 |
Why?
| | Down-Regulation | 2 | 2006 | 618 | 0.210 |
Why?
| | Interferon-gamma | 1 | 2008 | 784 | 0.210 |
Why?
| | Adenosine Triphosphate | 4 | 1995 | 500 | 0.210 |
Why?
| | Immunologic Tests | 1 | 2024 | 16 | 0.210 |
Why?
| | Biomarkers | 3 | 2024 | 4302 | 0.200 |
Why?
| | Skin Tests | 4 | 2013 | 94 | 0.200 |
Why?
| | Cell Nucleus | 1 | 2007 | 588 | 0.200 |
Why?
| | Pistacia | 1 | 2023 | 2 | 0.190 |
Why?
| | Anacardium | 1 | 2023 | 3 | 0.190 |
Why?
| | Juglans | 1 | 2023 | 8 | 0.190 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2010 | 2181 | 0.190 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2003 | 82 | 0.190 |
Why?
| | NF-kappa B | 1 | 2007 | 667 | 0.190 |
Why?
| | Alanine | 1 | 2023 | 169 | 0.180 |
Why?
| | Hypergammaglobulinemia | 3 | 1987 | 8 | 0.180 |
Why?
| | Hospitalization | 1 | 2013 | 2461 | 0.180 |
Why?
| | Arachidonate 5-Lipoxygenase | 2 | 2006 | 37 | 0.180 |
Why?
| | Bone Marrow | 3 | 2021 | 307 | 0.180 |
Why?
| | Anti-Bacterial Agents | 1 | 2013 | 1925 | 0.180 |
Why?
| | Nasal Mucosa | 1 | 2002 | 112 | 0.170 |
Why?
| | Basophil Degranulation Test | 3 | 2012 | 6 | 0.170 |
Why?
| | Mice | 9 | 2022 | 18355 | 0.170 |
Why?
| | Common Variable Immunodeficiency | 1 | 2001 | 26 | 0.170 |
Why?
| | Detergents | 1 | 2001 | 43 | 0.170 |
Why?
| | Cytological Techniques | 1 | 2001 | 27 | 0.170 |
Why?
| | Histamine | 3 | 2012 | 52 | 0.170 |
Why?
| | Child, Preschool | 8 | 2019 | 11868 | 0.170 |
Why?
| | Sesamum | 1 | 2020 | 6 | 0.160 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2001 | 70 | 0.160 |
Why?
| | Antigens, Differentiation, B-Lymphocyte | 3 | 1991 | 36 | 0.160 |
Why?
| | Ethnopharmacology | 1 | 2000 | 1 | 0.160 |
Why?
| | Cell Membrane | 5 | 1995 | 709 | 0.160 |
Why?
| | Female | 23 | 2019 | 79045 | 0.160 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2007 | 1217 | 0.160 |
Why?
| | Middle Aged | 15 | 2015 | 36309 | 0.160 |
Why?
| | Drugs, Chinese Herbal | 1 | 2000 | 24 | 0.160 |
Why?
| | Antigens | 3 | 1996 | 348 | 0.160 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2021 | 129 | 0.160 |
Why?
| | Enzyme Activation | 6 | 2001 | 762 | 0.150 |
Why?
| | Phosphoenolpyruvate | 3 | 1995 | 3 | 0.150 |
Why?
| | Pneumonia | 1 | 2006 | 636 | 0.150 |
Why?
| | Immunoblotting | 2 | 2011 | 295 | 0.150 |
Why?
| | Antibodies, Monoclonal | 2 | 2019 | 1505 | 0.150 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2001 | 288 | 0.150 |
Why?
| | Histocompatibility Antigens | 2 | 2013 | 102 | 0.150 |
Why?
| | Nonprescription Drugs | 1 | 2000 | 69 | 0.150 |
Why?
| | Monocytes | 2 | 2007 | 539 | 0.150 |
Why?
| | Dyspnea | 1 | 2001 | 250 | 0.150 |
Why?
| | Adhesins, Escherichia coli | 1 | 1999 | 1 | 0.150 |
Why?
| | Adult | 16 | 2015 | 40881 | 0.150 |
Why?
| | Mycoses | 1 | 2000 | 88 | 0.140 |
Why?
| | Fimbriae Proteins | 1 | 1999 | 25 | 0.140 |
Why?
| | Adhesins, Bacterial | 1 | 1999 | 44 | 0.140 |
Why?
| | Gastrointestinal Tract | 1 | 2021 | 204 | 0.140 |
Why?
| | Inflammation | 3 | 2007 | 2884 | 0.140 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 2 | 2009 | 110 | 0.140 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2009 | 143 | 0.130 |
Why?
| | Awards and Prizes | 1 | 2018 | 71 | 0.130 |
Why?
| | History, 21st Century | 1 | 2018 | 222 | 0.130 |
Why?
| | Triamcinolone | 1 | 1997 | 12 | 0.130 |
Why?
| | Binding Sites | 2 | 2016 | 1311 | 0.130 |
Why?
| | Myoclonus | 1 | 1997 | 16 | 0.130 |
Why?
| | Phosphocreatine | 2 | 1995 | 44 | 0.130 |
Why?
| | History, 20th Century | 1 | 2018 | 328 | 0.130 |
Why?
| | Sinusitis | 1 | 2000 | 227 | 0.130 |
Why?
| | Molecular Mimicry | 1 | 2017 | 36 | 0.130 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1997 | 43 | 0.130 |
Why?
| | Administration, Oral | 1 | 2019 | 867 | 0.120 |
Why?
| | Calcimycin | 1 | 1996 | 36 | 0.120 |
Why?
| | Lidocaine | 1 | 1997 | 55 | 0.120 |
Why?
| | Consensus Sequence | 1 | 2016 | 73 | 0.120 |
Why?
| | Cell Surface Display Techniques | 1 | 2016 | 13 | 0.120 |
Why?
| | Skin | 1 | 2021 | 754 | 0.120 |
Why?
| | Arachidonic Acid | 1 | 1996 | 102 | 0.120 |
Why?
| | Anesthetics, Local | 1 | 1997 | 104 | 0.120 |
Why?
| | Leukocyte Common Antigens | 1 | 2016 | 87 | 0.120 |
Why?
| | Immunophenotyping | 2 | 2016 | 322 | 0.120 |
Why?
| | Magnesium | 2 | 1993 | 157 | 0.120 |
Why?
| | Adolescent | 9 | 2019 | 22577 | 0.120 |
Why?
| | Chemokine CCL2 | 1 | 2016 | 112 | 0.110 |
Why?
| | Adoptive Transfer | 1 | 2016 | 200 | 0.110 |
Why?
| | B-Lymphocyte Subsets | 1 | 2016 | 76 | 0.110 |
Why?
| | Male | 14 | 2019 | 73010 | 0.110 |
Why?
| | Cytokines | 5 | 2018 | 2069 | 0.110 |
Why?
| | Child | 10 | 2015 | 22740 | 0.110 |
Why?
| | Bacteriophages | 1 | 2017 | 110 | 0.110 |
Why?
| | Mice, Inbred BALB C | 3 | 2006 | 1261 | 0.110 |
Why?
| | Protein Array Analysis | 1 | 2015 | 56 | 0.110 |
Why?
| | Influenza A Virus, H1N1 Subtype | 2 | 2013 | 159 | 0.110 |
Why?
| | Prostaglandin D2 | 3 | 2006 | 21 | 0.110 |
Why?
| | Lung Diseases | 1 | 2001 | 782 | 0.110 |
Why?
| | Chromatography, Liquid | 2 | 2023 | 450 | 0.100 |
Why?
| | Tryptases | 2 | 2012 | 12 | 0.100 |
Why?
| | Antigens, Dermatophagoides | 1 | 2014 | 10 | 0.100 |
Why?
| | gamma-Tocopherol | 1 | 2014 | 8 | 0.100 |
Why?
| | Asthma | 1 | 2006 | 1797 | 0.100 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2013 | 261 | 0.100 |
Why?
| | Cyclooxygenase 2 | 2 | 2006 | 167 | 0.100 |
Why?
| | Vitamin E | 1 | 2014 | 125 | 0.100 |
Why?
| | Genes, fos | 1 | 1993 | 36 | 0.100 |
Why?
| | Lung Transplantation | 1 | 1997 | 332 | 0.100 |
Why?
| | Cluster Analysis | 1 | 2015 | 501 | 0.100 |
Why?
| | Cats | 2 | 2004 | 234 | 0.100 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2006 | 638 | 0.100 |
Why?
| | Macrophages | 1 | 2001 | 1507 | 0.100 |
Why?
| | Tandem Mass Spectrometry | 2 | 2023 | 572 | 0.100 |
Why?
| | Headache | 1 | 2014 | 151 | 0.090 |
Why?
| | Pichia | 1 | 2012 | 20 | 0.090 |
Why?
| | Diagnosis, Differential | 4 | 2008 | 1512 | 0.090 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2012 | 331 | 0.090 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2007 | 979 | 0.090 |
Why?
| | Mutant Proteins | 1 | 2012 | 105 | 0.090 |
Why?
| | Albumins | 2 | 2023 | 119 | 0.090 |
Why?
| | Transfection | 2 | 2007 | 927 | 0.090 |
Why?
| | Drug Administration Schedule | 1 | 2014 | 782 | 0.090 |
Why?
| | Blotting, Western | 2 | 2007 | 1184 | 0.090 |
Why?
| | Complex Mixtures | 1 | 2011 | 11 | 0.090 |
Why?
| | Genetic Predisposition to Disease | 3 | 2010 | 2399 | 0.090 |
Why?
| | Proteomics | 1 | 2018 | 1188 | 0.080 |
Why?
| | Histamine Release | 3 | 2013 | 10 | 0.080 |
Why?
| | Lipopolysaccharides | 2 | 2007 | 858 | 0.080 |
Why?
| | Phosphoric Diester Hydrolases | 2 | 2006 | 52 | 0.080 |
Why?
| | Case-Control Studies | 1 | 2018 | 3634 | 0.080 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2007 | 849 | 0.080 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 2 | 2003 | 76 | 0.080 |
Why?
| | Algorithms | 2 | 2008 | 1851 | 0.080 |
Why?
| | Antibody Formation | 1 | 2011 | 288 | 0.080 |
Why?
| | HLA-DRB1 Chains | 1 | 2010 | 110 | 0.080 |
Why?
| | Pharmacists | 1 | 2013 | 258 | 0.080 |
Why?
| | Siblings | 1 | 2010 | 196 | 0.080 |
Why?
| | Autoantibodies | 2 | 2009 | 1509 | 0.080 |
Why?
| | Medical Records | 1 | 2010 | 192 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 2028 | 0.070 |
Why?
| | Respiratory Tract Infections | 1 | 2014 | 396 | 0.070 |
Why?
| | Gene Frequency | 1 | 2010 | 489 | 0.070 |
Why?
| | Chromatography, Gel | 1 | 2009 | 130 | 0.070 |
Why?
| | Ovalbumin | 2 | 2006 | 194 | 0.070 |
Why?
| | Molecular Weight | 1 | 2009 | 312 | 0.070 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2010 | 364 | 0.070 |
Why?
| | Dermatitis, Allergic Contact | 1 | 2009 | 73 | 0.070 |
Why?
| | Haplotypes | 1 | 2010 | 500 | 0.070 |
Why?
| | Cytoplasm | 1 | 1989 | 254 | 0.070 |
Why?
| | Clinical Trials as Topic | 1 | 2014 | 1062 | 0.070 |
Why?
| | Diphenhydramine | 1 | 2008 | 36 | 0.070 |
Why?
| | Th2 Cells | 2 | 2006 | 175 | 0.070 |
Why?
| | Histamine H1 Antagonists | 1 | 2008 | 24 | 0.070 |
Why?
| | Phenotype | 1 | 2016 | 3170 | 0.070 |
Why?
| | Aged | 4 | 2015 | 26217 | 0.070 |
Why?
| | Administration, Intranasal | 1 | 2008 | 94 | 0.070 |
Why?
| | Escherichia coli | 1 | 2012 | 835 | 0.070 |
Why?
| | Infant | 5 | 2013 | 10091 | 0.070 |
Why?
| | Epinephrine | 1 | 2008 | 158 | 0.070 |
Why?
| | Membrane Proteins | 2 | 2005 | 1166 | 0.070 |
Why?
| | Young Adult | 3 | 2015 | 14254 | 0.070 |
Why?
| | Interleukin-4 | 1 | 2008 | 207 | 0.060 |
Why?
| | Abscess | 1 | 1987 | 77 | 0.060 |
Why?
| | HMGB1 Protein | 1 | 2007 | 51 | 0.060 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2007 | 23 | 0.060 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2007 | 75 | 0.060 |
Why?
| | Polysaccharides, Bacterial | 1 | 2007 | 69 | 0.060 |
Why?
| | Immunotherapy | 2 | 2009 | 668 | 0.060 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2007 | 88 | 0.060 |
Why?
| | Immunoprecipitation | 1 | 2007 | 149 | 0.060 |
Why?
| | Lysine | 2 | 2001 | 305 | 0.060 |
Why?
| | Transcription Factor RelA | 1 | 2007 | 86 | 0.060 |
Why?
| | ZAP-70 Protein-Tyrosine Kinase | 1 | 2006 | 10 | 0.060 |
Why?
| | Cyclooxygenase 1 | 1 | 2006 | 27 | 0.060 |
Why?
| | Nigella sativa | 1 | 2006 | 1 | 0.060 |
Why?
| | Endotoxins | 1 | 2007 | 217 | 0.060 |
Why?
| | Dermatitis, Atopic | 1 | 2009 | 322 | 0.060 |
Why?
| | Goblet Cells | 1 | 2006 | 22 | 0.060 |
Why?
| | United States | 4 | 2018 | 16126 | 0.060 |
Why?
| | Pyrophosphatases | 1 | 2006 | 26 | 0.060 |
Why?
| | Serum | 1 | 2006 | 58 | 0.060 |
Why?
| | Staphylococcal Infections | 2 | 1987 | 393 | 0.060 |
Why?
| | Thyroiditis, Autoimmune | 1 | 2005 | 16 | 0.060 |
Why?
| | Plasmids | 1 | 2007 | 373 | 0.060 |
Why?
| | Bronchial Hyperreactivity | 1 | 2006 | 104 | 0.060 |
Why?
| | Alopecia Areata | 1 | 2005 | 13 | 0.060 |
Why?
| | Immunochemistry | 1 | 2005 | 12 | 0.060 |
Why?
| | Vitiligo | 1 | 2005 | 42 | 0.060 |
Why?
| | Leukocyte Count | 1 | 2006 | 318 | 0.060 |
Why?
| | Environmental Exposure | 2 | 2009 | 578 | 0.060 |
Why?
| | Time Factors | 3 | 2011 | 7134 | 0.060 |
Why?
| | Thyroid Hormones | 1 | 2005 | 69 | 0.060 |
Why?
| | Haptens | 2 | 1996 | 25 | 0.050 |
Why?
| | Databases, Factual | 1 | 2011 | 1491 | 0.050 |
Why?
| | Acute Disease | 1 | 2008 | 1036 | 0.050 |
Why?
| | Toll-Like Receptors | 1 | 2006 | 193 | 0.050 |
Why?
| | Biological Assay | 1 | 2005 | 132 | 0.050 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2001 | 431 | 0.050 |
Why?
| | Cell Line, Tumor | 1 | 2012 | 3551 | 0.050 |
Why?
| | Staphylococcus aureus | 2 | 1987 | 454 | 0.050 |
Why?
| | Antibodies, Bacterial | 1 | 1985 | 147 | 0.050 |
Why?
| | Physicians | 1 | 2013 | 956 | 0.050 |
Why?
| | Sequence Alignment | 2 | 2014 | 362 | 0.050 |
Why?
| | Immunoglobulin A | 1 | 1985 | 214 | 0.050 |
Why?
| | Vaccines | 1 | 2008 | 389 | 0.050 |
Why?
| | Cyclooxygenase 2 Inhibitors | 1 | 2003 | 24 | 0.050 |
Why?
| | Seed Storage Proteins | 1 | 2023 | 1 | 0.050 |
Why?
| | Immunologic Techniques | 1 | 2003 | 38 | 0.050 |
Why?
| | Nut Hypersensitivity | 1 | 2023 | 5 | 0.050 |
Why?
| | Up-Regulation | 1 | 2006 | 848 | 0.050 |
Why?
| | Antibody Specificity | 2 | 2003 | 179 | 0.050 |
Why?
| | Lung | 2 | 2006 | 4116 | 0.050 |
Why?
| | Enzyme Inhibitors | 1 | 2006 | 821 | 0.050 |
Why?
| | Severity of Illness Index | 1 | 2010 | 2933 | 0.050 |
Why?
| | Cell Count | 2 | 2021 | 319 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2007 | 1247 | 0.040 |
Why?
| | Signal Transduction | 4 | 2007 | 5224 | 0.040 |
Why?
| | Hypereosinophilic Syndrome | 1 | 2021 | 8 | 0.040 |
Why?
| | MAP Kinase Kinase Kinase 3 | 1 | 2001 | 4 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinase 10 | 1 | 2001 | 4 | 0.040 |
Why?
| | Octoxynol | 1 | 2001 | 12 | 0.040 |
Why?
| | MAP Kinase Kinase Kinase 2 | 1 | 2001 | 12 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinase 8 | 1 | 2001 | 14 | 0.040 |
Why?
| | Mastocytosis | 1 | 2021 | 14 | 0.040 |
Why?
| | Precipitin Tests | 1 | 2001 | 90 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinase 9 | 1 | 2001 | 17 | 0.040 |
Why?
| | Immune Sera | 1 | 2001 | 77 | 0.040 |
Why?
| | Biopsy | 2 | 2021 | 1082 | 0.040 |
Why?
| | Enzyme Stability | 1 | 2001 | 73 | 0.040 |
Why?
| | Reproducibility of Results | 1 | 2009 | 3418 | 0.040 |
Why?
| | Valine | 1 | 2001 | 83 | 0.040 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2001 | 153 | 0.040 |
Why?
| | Exocytosis | 2 | 1993 | 85 | 0.040 |
Why?
| | Hydrolysis | 2 | 1993 | 197 | 0.040 |
Why?
| | Bacterial Infections | 1 | 1983 | 247 | 0.040 |
Why?
| | T-Lymphocytes | 2 | 2018 | 1998 | 0.040 |
Why?
| | Treatment Outcome | 2 | 2014 | 11794 | 0.040 |
Why?
| | Serine | 1 | 2001 | 143 | 0.040 |
Why?
| | Shock, Septic | 1 | 1983 | 227 | 0.040 |
Why?
| | Leukemia | 1 | 1983 | 246 | 0.040 |
Why?
| | Medicine, Traditional | 1 | 2000 | 23 | 0.040 |
Why?
| | Transcription, Genetic | 1 | 2007 | 1454 | 0.040 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2001 | 376 | 0.040 |
Why?
| | Catalysis | 1 | 2001 | 305 | 0.040 |
Why?
| | Gastritis | 1 | 2021 | 117 | 0.040 |
Why?
| | Radioallergosorbent Test | 1 | 2000 | 3 | 0.040 |
Why?
| | Environmental Illness | 1 | 2000 | 3 | 0.040 |
Why?
| | Enteritis | 1 | 2021 | 105 | 0.040 |
Why?
| | Hypersensitivity, Delayed | 1 | 2000 | 29 | 0.040 |
Why?
| | Growth Hormone | 1 | 1980 | 91 | 0.040 |
Why?
| | Interleukin-3 | 2 | 1989 | 23 | 0.040 |
Why?
| | Protein Domains | 1 | 2021 | 311 | 0.040 |
Why?
| | Calcium | 3 | 1991 | 1191 | 0.040 |
Why?
| | Mannose | 1 | 1999 | 23 | 0.040 |
Why?
| | Eosinophilia | 1 | 2021 | 224 | 0.040 |
Why?
| | Serotonin | 1 | 2001 | 298 | 0.040 |
Why?
| | Muscles | 1 | 1980 | 330 | 0.040 |
Why?
| | Mice, Inbred C3H | 1 | 1999 | 254 | 0.040 |
Why?
| | Ribosomes | 1 | 1980 | 193 | 0.030 |
Why?
| | Prevalence | 1 | 2005 | 2875 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2003 | 2000 | 0.030 |
Why?
| | Drug Prescriptions | 1 | 2000 | 288 | 0.030 |
Why?
| | Subdural Space | 1 | 1997 | 7 | 0.030 |
Why?
| | Injections, Epidural | 1 | 1997 | 28 | 0.030 |
Why?
| | Eosinophilic Esophagitis | 1 | 2021 | 332 | 0.030 |
Why?
| | Leukotriene C4 | 1 | 1996 | 6 | 0.030 |
Why?
| | Phosphorylation | 1 | 2001 | 1708 | 0.030 |
Why?
| | Latex | 1 | 1996 | 9 | 0.030 |
Why?
| | Antibody Affinity | 1 | 1996 | 60 | 0.030 |
Why?
| | Rubber | 1 | 1996 | 8 | 0.030 |
Why?
| | Steroids | 1 | 1997 | 160 | 0.030 |
Why?
| | Polyethylene Glycols | 1 | 2001 | 649 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2009 | 6085 | 0.030 |
Why?
| | Hypotension | 1 | 1997 | 127 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2018 | 507 | 0.030 |
Why?
| | Cell Fractionation | 2 | 1989 | 50 | 0.030 |
Why?
| | Adenosine-5'-(N-ethylcarboxamide) | 1 | 1995 | 9 | 0.030 |
Why?
| | Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 1995 | 15 | 0.030 |
Why?
| | Vanadates | 1 | 1995 | 17 | 0.030 |
Why?
| | Double-Blind Method | 3 | 2006 | 2064 | 0.030 |
Why?
| | Oligonucleotides | 1 | 1996 | 153 | 0.030 |
Why?
| | Drug Interactions | 1 | 1996 | 405 | 0.030 |
Why?
| | Hydroxylation | 1 | 2014 | 47 | 0.030 |
Why?
| | Cell Membrane Permeability | 1 | 1995 | 88 | 0.030 |
Why?
| | Leukotriene D4 | 1 | 2014 | 1 | 0.030 |
Why?
| | Dose-Response Relationship, Immunologic | 2 | 2004 | 76 | 0.030 |
Why?
| | Dinitrobenzenes | 1 | 1993 | 5 | 0.030 |
Why?
| | Receptor Aggregation | 1 | 1993 | 10 | 0.030 |
Why?
| | Phosphotyrosine | 1 | 1993 | 38 | 0.030 |
Why?
| | Recombinant Proteins | 3 | 2012 | 1368 | 0.030 |
Why?
| | Adenosine | 1 | 1995 | 255 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2001 | 2050 | 0.020 |
Why?
| | Mass Vaccination | 1 | 2013 | 18 | 0.020 |
Why?
| | Tyrosine | 1 | 1993 | 217 | 0.020 |
Why?
| | Permeability | 1 | 1993 | 169 | 0.020 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2013 | 81 | 0.020 |
Why?
| | Receptors, Interleukin-2 | 2 | 2004 | 64 | 0.020 |
Why?
| | Leukocytes | 1 | 1974 | 296 | 0.020 |
Why?
| | Protein Kinase C | 1 | 1993 | 251 | 0.020 |
Why?
| | Circular Dichroism | 1 | 2012 | 151 | 0.020 |
Why?
| | Clone Cells | 1 | 2012 | 263 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 1993 | 1049 | 0.020 |
Why?
| | Phosphatidylinositol Diacylglycerol-Lyase | 1 | 1991 | 4 | 0.020 |
Why?
| | Phosphoinositide Phospholipase C | 1 | 1991 | 5 | 0.020 |
Why?
| | Air Pollutants | 1 | 1996 | 407 | 0.020 |
Why?
| | Kinetics | 1 | 2014 | 1568 | 0.020 |
Why?
| | Subcellular Fractions | 1 | 1991 | 73 | 0.020 |
Why?
| | Point Mutation | 1 | 2012 | 241 | 0.020 |
Why?
| | Phosphoproteins | 1 | 1993 | 337 | 0.020 |
Why?
| | DNA | 2 | 1996 | 1437 | 0.020 |
Why?
| | Protein Folding | 1 | 2012 | 277 | 0.020 |
Why?
| | Microscopy, Electron | 1 | 1991 | 414 | 0.020 |
Why?
| | Pruritus | 1 | 2010 | 60 | 0.020 |
Why?
| | Pemphigus | 1 | 2009 | 8 | 0.020 |
Why?
| | Rosette Formation | 1 | 1989 | 14 | 0.020 |
Why?
| | Staphylococcal Protein A | 1 | 1989 | 12 | 0.020 |
Why?
| | Flow Cytometry | 2 | 2004 | 1165 | 0.020 |
Why?
| | Energy Metabolism | 1 | 1995 | 935 | 0.020 |
Why?
| | Extracellular Space | 1 | 1989 | 117 | 0.020 |
Why?
| | Thyroxine | 1 | 2009 | 67 | 0.020 |
Why?
| | Psoriasis | 1 | 2009 | 115 | 0.020 |
Why?
| | Adaptive Immunity | 1 | 2009 | 167 | 0.020 |
Why?
| | Immunoglobulin Fc Fragments | 1 | 1988 | 41 | 0.020 |
Why?
| | Vasoconstrictor Agents | 1 | 2008 | 150 | 0.020 |
Why?
| | Body Fluid Compartments | 1 | 1987 | 6 | 0.020 |
Why?
| | Sex Factors | 1 | 2013 | 2110 | 0.020 |
Why?
| | Influenza, Human | 1 | 2013 | 624 | 0.020 |
Why?
| | Ribonucleases | 2 | 1980 | 48 | 0.020 |
Why?
| | Metabolic Clearance Rate | 1 | 1987 | 115 | 0.020 |
Why?
| | Dermatitis, Contact | 1 | 1987 | 18 | 0.020 |
Why?
| | Rhinometry, Acoustic | 1 | 2006 | 1 | 0.020 |
Why?
| | IgG Deficiency | 1 | 2006 | 6 | 0.020 |
Why?
| | Interviews as Topic | 1 | 2010 | 916 | 0.010 |
Why?
| | Necrosis | 1 | 2007 | 244 | 0.010 |
Why?
| | Bronchial Provocation Tests | 1 | 2006 | 47 | 0.010 |
Why?
| | Psychometrics | 1 | 2010 | 732 | 0.010 |
Why?
| | Interleukin-8 | 1 | 2007 | 269 | 0.010 |
Why?
| | Cells, Cultured | 3 | 2007 | 4151 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2010 | 1115 | 0.010 |
Why?
| | Dinoprostone | 1 | 2006 | 180 | 0.010 |
Why?
| | Drug Therapy, Combination | 1 | 2008 | 1043 | 0.010 |
Why?
| | Serine Endopeptidases | 1 | 2006 | 129 | 0.010 |
Why?
| | Immunoglobulin A, Secretory | 1 | 1985 | 8 | 0.010 |
Why?
| | Immunoglobulin D | 1 | 1985 | 29 | 0.010 |
Why?
| | Granulomatous Disease, Chronic | 1 | 1985 | 49 | 0.010 |
Why?
| | Haemophilus Infections | 1 | 1985 | 46 | 0.010 |
Why?
| | Postoperative Complications | 1 | 1997 | 2977 | 0.010 |
Why?
| | Immunity, Innate | 1 | 2009 | 835 | 0.010 |
Why?
| | Cross-Over Studies | 1 | 2006 | 610 | 0.010 |
Why?
| | Immunoglobulin M | 1 | 1985 | 265 | 0.010 |
Why?
| | Agranulocytosis | 1 | 1983 | 30 | 0.010 |
Why?
| | Interleukin-6 | 1 | 2007 | 780 | 0.010 |
Why?
| | Disease Progression | 1 | 2010 | 2865 | 0.010 |
Why?
| | Peritonitis | 1 | 1983 | 83 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 1999 | 3937 | 0.010 |
Why?
| | Transforming Growth Factor beta | 1 | 2004 | 474 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2013 | 6465 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2013 | 8347 | 0.010 |
Why?
| | Hypophysectomy | 1 | 1980 | 12 | 0.010 |
Why?
| | Puromycin | 1 | 1980 | 10 | 0.010 |
Why?
| | Centrifugation, Density Gradient | 1 | 1980 | 36 | 0.010 |
Why?
| | Peptide Biosynthesis | 1 | 1980 | 13 | 0.010 |
Why?
| | Thy-1 Antigens | 1 | 1999 | 11 | 0.010 |
Why?
| | Concanavalin A | 1 | 1999 | 72 | 0.010 |
Why?
| | Leucine | 1 | 1980 | 116 | 0.010 |
Why?
| | CD28 Antigens | 1 | 1999 | 59 | 0.010 |
Why?
| | Mitogens | 1 | 1999 | 55 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2008 | 5428 | 0.010 |
Why?
| | Rats, Inbred F344 | 1 | 1999 | 268 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2006 | 2601 | 0.010 |
Why?
| | Serotonin Antagonists | 1 | 1996 | 32 | 0.010 |
Why?
| | Binding, Competitive | 1 | 1996 | 185 | 0.010 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2003 | 1146 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 1999 | 673 | 0.010 |
Why?
| | Photomicrography | 1 | 1974 | 8 | 0.010 |
Why?
| | Ligands | 1 | 1996 | 668 | 0.010 |
Why?
| | Aspergillus | 1 | 1974 | 18 | 0.010 |
Why?
| | Nucleic Acid Denaturation | 1 | 1974 | 32 | 0.010 |
Why?
| | Methods | 1 | 1974 | 68 | 0.010 |
Why?
| | Deoxyribonucleases | 1 | 1974 | 24 | 0.010 |
Why?
| | Chromatography, Ion Exchange | 1 | 1974 | 57 | 0.010 |
Why?
| | Spectrophotometry | 1 | 1974 | 58 | 0.010 |
Why?
| | Histocytochemistry | 1 | 1974 | 78 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1974 | 164 | 0.010 |
Why?
| | Freezing | 1 | 1974 | 83 | 0.010 |
Why?
| | Staining and Labeling | 1 | 1974 | 153 | 0.010 |
Why?
| | Nucleic Acid Conformation | 1 | 1996 | 724 | 0.010 |
Why?
| | DNA, Single-Stranded | 1 | 1974 | 117 | 0.010 |
Why?
| | Base Sequence | 1 | 1996 | 2171 | 0.010 |
Why?
| | Pancreas | 1 | 1974 | 341 | 0.010 |
Why?
| | Hot Temperature | 1 | 1974 | 396 | 0.010 |
Why?
| | RNA | 1 | 1996 | 912 | 0.000 |
Why?
| | Chromatin | 1 | 1974 | 553 | 0.000 |
Why?
| | Interphase | 1 | 1989 | 38 | 0.000 |
Why?
| | Ethanol | 1 | 1974 | 631 | 0.000 |
Why?
| | Peptide Hydrolases | 1 | 1989 | 105 | 0.000 |
Why?
| | Cell Division | 1 | 1989 | 757 | 0.000 |
Why?
| | Extracellular Matrix | 1 | 1989 | 563 | 0.000 |
Why?
|
|
Dreskin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|